来自官方财务报表的收入、利润与现金流历史。
雅培实验室及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它的业务分为四个部门：成熟的药品部门、诊断产品部门、营养产品部门和医疗器械部门。该公司提供治疗胰腺外分泌功能不全、肠易激综合征或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退症、高甘油三酯血症、梅尼埃病和前庭眩晕、疼痛、发烧、炎症和偏头痛的仿制药，并提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。它还提供免疫分析、临床化学、血液学和输血血清学检测领域的实验室和输血医学系统；分子诊断聚合酶链反应仪器系统，可自动从患者样本中提取、纯化和制备 DNA 和 RNA，并检测和测量传染原；护理点系统；用于测试血气、化学、电解质、凝血和免疫测定的试剂盒；快速诊断侧向层析检测产品； HIV、SARS-CoV-2、甲型和乙型流感、RSV 和 A 型链球菌的分子护理点检测；心脏代谢测试系统；以及药物和酒精测试。此外，该公司还提供儿科和成人营养产品以及婴儿配方奶粉；用于治疗心血管疾病的节律管理、电生理学、心力衰竭、血管和结构性心脏装置；糖尿病护理产品，例如血糖和血糖监测系统；和神经调节装置。比较
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $46.6B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B | $20.4B | $20.2B | $21.8B | $39.9B | $38.9B | $35.2B | $30.8B | $29.5B | $25.9B | $22.5B |
| 毛利 | $26.5B | $24.6B | $21.3B | $20.0B | $22.3B | $23.2B | $17.4B | $16.7B | $15.8B | $13.1B | $11.2B | $11.0B | $10.5B | $9.9B | $10.9B | $23.4B | $20.6B | $17.6B | $17.0B | $14.6B | $12.8B |
| 毛利率% | 56.8% | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% | 52.3% | 51.7% | 47.7% | 53.9% | 53.7% | 51.8% | 45.1% | 27.2% | 60.3% | 58.6% | 57.3% | 57.7% | 56.3% | 57.1% |
| 营业利润（EBIT） | $7.9B | $8.0B | $6.8B | $6.4B | $8.4B | $9.2B | $5.3B | $4.6B | $3.8B | $2.0B | $3.2B | $2.9B | $2.9B | $2.1B | $2.0B | $6.8B | $7.1B | $6.6B | $6.1B | $4.9B | $4.3B |
| 营业利润率% | 17.0% | 18.2% | 16.3% | 16.0% | 19.2% | 21.4% | 15.3% | 14.4% | 12.6% | 7.2% | 15.6% | 14.4% | 14.4% | 9.8% | 5.0% | 17.6% | 20.1% | 21.4% | 20.6% | 19.1% | 19.3% |
| 净利 | $5.4B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477M | $1.4B | $4.4B | $2.3B | $2.6B | $6.0B | $4.7B | $4.6B | $5.7B | $4.9B | $3.6B | $1.7B |
| 净利润率 % | 11.7% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% | 11.3% | 11.8% | 14.9% | 12.2% | 13.2% | 18.7% | 16.5% | 13.9% | 7.6% |
| EBITDA | $9.9B | $11.6B | $10.8B | $10.6B | $11.9B | $12.2B | $9.0B | $7.9B | $6.9B | $6.1B | $3.1B | $4.8B | $4.2B | $3.6B | $3.5B | $9.3B | $9.1B | $9.5B | $8.2B | $6.9B | $4.3B |
| 每股收益（EPS） | $3.11 | $3.73 | $7.67 | $3.27 | $3.93 | $3.95 | $2.52 | $2.07 | $1.34 | $0.27 | $0.94 | $2.94 | $1.50 | $1.64 | $3.75 | $3.01 | $2.97 | $3.70 | $3.13 | $2.31 | $1.12 |
| 已发行股数 (M) | 1,743M | 1,747M | 1,748M | 1,749M | 1,764M | 1,789M | 1,786M | 1,781M | 1,770M | 1,749M | 1,483M | 1,506M | 1,527M | 1,574M | 1,592M | 1,570M | 1,556M | 1,555M | 1,561M | 1,560M | 1,537M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 ABT 交互式查看器。 /companies/us/ABT
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms